MA34647B1 - Procedes de traitement de la polyarthriterhumatoide en utilisant des antagonistes dil-17 - Google Patents
Procedes de traitement de la polyarthriterhumatoide en utilisant des antagonistes dil-17Info
- Publication number
- MA34647B1 MA34647B1 MA35873A MA35873A MA34647B1 MA 34647 B1 MA34647 B1 MA 34647B1 MA 35873 A MA35873 A MA 35873A MA 35873 A MA35873 A MA 35873A MA 34647 B1 MA34647 B1 MA 34647B1
- Authority
- MA
- Morocco
- Prior art keywords
- polyarthriterhumatoid
- dil
- antagonists
- treating
- methods
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 206010003230 arteritis Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 229960004540 secukinumab Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41053310P | 2010-11-05 | 2010-11-05 | |
| PCT/EP2011/069476 WO2012059598A2 (en) | 2010-11-05 | 2011-11-04 | Methods of treating rheumatoid arthritis using il-17 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34647B1 true MA34647B1 (fr) | 2013-11-02 |
Family
ID=44906168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA35873A MA34647B1 (fr) | 2010-11-05 | 2013-05-03 | Procedes de traitement de la polyarthriterhumatoide en utilisant des antagonistes dil-17 |
Country Status (31)
| Country | Link |
|---|---|
| US (10) | US9744234B2 (enExample) |
| EP (6) | EP3542820A1 (enExample) |
| JP (8) | JP2014503482A (enExample) |
| KR (5) | KR20140008305A (enExample) |
| CN (2) | CN103189074A (enExample) |
| AU (1) | AU2011325134B2 (enExample) |
| BR (1) | BR112013011176A2 (enExample) |
| CA (2) | CA2813849C (enExample) |
| CL (1) | CL2013001213A1 (enExample) |
| CY (1) | CY1121802T1 (enExample) |
| DE (1) | DE20187001T1 (enExample) |
| DK (2) | DK3111954T3 (enExample) |
| ES (3) | ES2733712T3 (enExample) |
| FI (1) | FI3757126T3 (enExample) |
| HR (2) | HRP20251174T1 (enExample) |
| HU (1) | HUE044038T2 (enExample) |
| IL (4) | IL311014A (enExample) |
| LT (2) | LT3111954T (enExample) |
| MA (1) | MA34647B1 (enExample) |
| MX (1) | MX362591B (enExample) |
| PH (1) | PH12013500890A1 (enExample) |
| PL (1) | PL3111954T3 (enExample) |
| PT (2) | PT3111954T (enExample) |
| RS (1) | RS67377B1 (enExample) |
| RU (1) | RU2582937C2 (enExample) |
| SG (2) | SG189138A1 (enExample) |
| SI (2) | SI3757126T1 (enExample) |
| SM (1) | SMT202500423T1 (enExample) |
| TR (1) | TR201909531T4 (enExample) |
| TW (3) | TWI616204B (enExample) |
| WO (1) | WO2012059598A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011254557B2 (en) | 2010-05-20 | 2015-09-03 | Ablynx Nv | Biological materials related to HER3 |
| KR20140008305A (ko) * | 2010-11-05 | 2014-01-21 | 노파르티스 아게 | Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법 |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| WO2013055745A2 (en) | 2011-10-11 | 2013-04-18 | Medimmune, Llc | Cd40l-specific tn3-derived scaffolds and methods of use thereof |
| US9284283B2 (en) | 2012-02-02 | 2016-03-15 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating IL-17 |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| EP3060250A1 (en) * | 2013-10-22 | 2016-08-31 | NovImmune SA | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers |
| US20160340422A1 (en) * | 2014-01-28 | 2016-11-24 | Beijing Hanmi Pharmaceutical Co., Ltd. | Bifunctional fusion protein, preparation method therefor, and use thereof |
| CN113230398B (zh) | 2014-05-13 | 2025-01-03 | 免疫医疗有限公司 | 用于治疗非小细胞肺癌的抗-b7-h1和抗-ctla-4抗体 |
| US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| AU2015258859B2 (en) | 2014-05-15 | 2020-07-23 | Rani Therapeutics, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| FR3021976B1 (fr) * | 2014-06-06 | 2018-11-02 | Hospices Civils De Lyon | Marqueur biologique permettant d'evaluer le niveau pro-inflammatoire dependant de la contribution fonctionnelle de l'il-17 chez un individu |
| WO2015191760A2 (en) * | 2014-06-10 | 2015-12-17 | Abbvie, Inc. | Compositions and methods for treating rheumatoid arthritis |
| NL2013007B1 (en) * | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| EP4406969A3 (en) * | 2014-09-10 | 2024-11-27 | Novartis AG | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients |
| AU2015336101A1 (en) * | 2014-10-22 | 2017-04-20 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| AR103172A1 (es) * | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
| AR103173A1 (es) * | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| HK1247562A1 (zh) | 2015-03-02 | 2018-09-28 | 180 Therapeutics Lp | 利用tnf受体2拮抗剂来治疗局部纤维化絮乱的方法 |
| EP3167892A1 (en) | 2015-11-10 | 2017-05-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases |
| AU2016342578A1 (en) * | 2015-10-19 | 2018-03-29 | Novartis Ag | Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (IL-17) antagonists |
| AU2017316513A1 (en) * | 2016-08-23 | 2019-03-28 | Csl Behring Gmbh | Method of preventing acute attacks of hereditary angioedema associated with C1 esterase inhibitor deficiency |
| KR20200083996A (ko) * | 2017-11-02 | 2020-07-09 | 노파르티스 아게 | 인터류킨-17(il-17)을 사용하여 건병증을 치료하는 방법 |
| GB201719447D0 (en) * | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
| EP3790576A1 (en) * | 2018-05-09 | 2021-03-17 | Novartis Ag | Use of canakinumab |
| AU2019346457B2 (en) * | 2018-09-26 | 2025-05-08 | Viela Bio, Inc. | CD40l antagonist and uses thereof |
| MX2021008696A (es) * | 2019-01-22 | 2021-08-19 | Hoffmann La Roche | Metodos para tratar artritis reumatoide, urticaria espontanea cronica y lupus eritematoso diseminado mediante el uso de un inhibidor de tirosina quinasa de bruton. |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| KR102169901B1 (ko) * | 2019-05-17 | 2020-10-26 | 연세대학교 산학협력단 | Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| CN110179746A (zh) | 2019-05-17 | 2019-08-30 | 通化东宝生物科技有限公司 | 一种稳定的苏金单抗注射剂及其制备方法 |
| MX2022001607A (es) * | 2019-08-05 | 2022-03-11 | Evelo Biosciences Inc | Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola. |
| JP2022549200A (ja) * | 2019-09-20 | 2022-11-24 | ノバルティス アーゲー | インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して自己免疫疾患を治療する方法 |
| KR20220103141A (ko) | 2019-11-19 | 2022-07-21 | 노파르티스 아게 | 인터류킨-17(il-17) 길항제를 사용하여 루푸스 신장염을 치료하는 방법 |
| CN112915201B (zh) * | 2019-12-06 | 2023-06-27 | 珠海市丽珠单抗生物技术有限公司 | 包含抗il-17抗体的液体制剂 |
| WO2021146850A1 (en) * | 2020-01-20 | 2021-07-29 | Tsinghua University | A critical role of febrile temperature in regulating interleukin (il) -17 producing cells via smad4 |
| US20240101659A1 (en) * | 2020-11-25 | 2024-03-28 | Dr. Reddy’S Laboratories Limited | Stable therapeutic protein formulation and methods of making the same |
| TW202241505A (zh) * | 2021-01-04 | 2022-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗il-17抗體治療自體免疫性疾病和炎症的方法 |
| WO2022184114A1 (zh) * | 2021-03-03 | 2022-09-09 | 苏州盛迪亚生物医药有限公司 | 抗il-17抗体治疗自身免疫性疾病和炎症的方法 |
| KR102339377B1 (ko) * | 2021-03-29 | 2021-12-13 | 김지혜 | 사용자 맞춤형 문화 예술 컨텐츠 제공 방법 및 장치 |
| KR20240024929A (ko) * | 2021-06-21 | 2024-02-26 | 브리스톨-마이어스 스큅 컴퍼니 | 고농도 동결건조 생물제제 약물 제품의 재구성 시간을 감소시키기 위한 수크로스, 만니톨 및 글리신의 용도 |
| CN114306594A (zh) * | 2021-12-21 | 2022-04-12 | 华中科技大学同济医学院附属协和医院 | 地舒单抗在制备治疗膝关节骨性关节炎的药物中的应用 |
| WO2024156841A1 (en) | 2023-01-27 | 2024-08-02 | Fresenius Kabi Deutschland Gmbh | Biopharmaceutical composition |
| EP4406553A1 (en) | 2023-01-27 | 2024-07-31 | Fresenius Kabi Deutschland GmbH | Stable secukinumab biopharmaceutical composition |
| WO2025071335A1 (ko) * | 2023-09-27 | 2025-04-03 | 삼성바이오에피스 주식회사 | 항-il-17 항체의 안정한 액상 제형 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0565233A (ja) | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
| US5250442A (en) * | 1993-04-08 | 1993-10-05 | Orestes Cabezas | Method of treating rheumatoid arthritis using tetracycline |
| US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US20050147609A1 (en) | 1998-05-15 | 2005-07-07 | Genentech, Inc. | Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis |
| JP2000186046A (ja) | 1998-10-14 | 2000-07-04 | Snow Brand Milk Prod Co Ltd | 慢性関節リウマチ治療剤及び診断方法 |
| ATE338120T2 (de) | 1998-11-27 | 2006-09-15 | Ucb Sa | Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| JP4159682B2 (ja) | 1998-12-22 | 2008-10-01 | 株式会社クラレ | 止血材 |
| DE60235013D1 (de) | 2001-07-25 | 2010-02-25 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| MXPA04004459A (es) | 2001-11-09 | 2005-05-16 | Johnson & Johnson | Composiciones liofilizadas de anticuerpo monoclonal. |
| EP2277522B1 (en) | 2002-03-01 | 2012-11-21 | UCB Manufacturing, Inc. | Methods for increasing or decreasing bone density and identifying molecules |
| US20040023356A1 (en) | 2002-06-14 | 2004-02-05 | Robb Krumlauf | Wise/Sost nucleic acid sequences and amino acid sequences |
| US6974701B2 (en) | 2003-03-21 | 2005-12-13 | Hemovations, Llc | Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same |
| NO345763B1 (no) | 2003-06-16 | 2021-07-19 | Celltech R&D Inc | Immunogen og antistoffer spesifikke for sklerostin, samt farmasøytiske preparater for å øke benmineralisering. |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US8039642B2 (en) | 2003-12-09 | 2011-10-18 | Life Technologies Corporation | Pyrenyloxysulfonic acid fluorescent agents |
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| JP3936365B2 (ja) | 2004-09-14 | 2007-06-27 | ソニーケミカル＆インフォメーションデバイス株式会社 | 機能素子実装モジュール及びその製造方法 |
| EP1858552A2 (en) | 2005-03-08 | 2007-11-28 | Pharmacia & Upjohn Company LLC | Composition comprising human igg2 antibody and a chelating agent |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US20090221568A1 (en) | 2005-11-04 | 2009-09-03 | Jared Shaw | Synthesis of Inhibitors of FtsZ |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| JP5231810B2 (ja) | 2005-12-28 | 2013-07-10 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| EP1984401A2 (en) | 2006-01-31 | 2008-10-29 | Novartis AG | Il-17 antagonistic antibodies fpr treating cancer |
| TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| CN101627055A (zh) | 2006-09-05 | 2010-01-13 | 梅达雷克斯公司 | 骨形成蛋白及其受体的抗体以及它们的使用方法 |
| WO2008029908A1 (fr) | 2006-09-07 | 2008-03-13 | Kyowa Hakko Kirin Co., Ltd. | Préparation pharmaceutique lyophilisée stable comprenant un anticorps |
| UA99716C2 (ru) * | 2006-10-02 | 2012-09-25 | Кирин-Амген Инк. | Антитело, которое специфично связывает человеческий il-17 рецептор а (il-17ra) |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| EP2460828A3 (en) | 2006-11-10 | 2012-08-08 | UCB Pharma, S.A. | Antibodies and diagnostics |
| EP2097450A2 (en) | 2006-11-10 | 2009-09-09 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| EP2114435A1 (en) | 2007-02-02 | 2009-11-11 | Novartis AG | Modulators of sclerostin binding partners for treating bone-related disorders |
| UA96474C2 (en) | 2007-03-20 | 2011-11-10 | Эли Лилли Энд Компани | Anti-sclerostin antibodies |
| EP2136839A4 (en) | 2007-03-22 | 2010-04-07 | Imclone Llc | STABLE ANTIBODY FORMULATIONS |
| CN101678103A (zh) * | 2007-03-30 | 2010-03-24 | 米迪缪尼股份有限公司 | 抗体制剂 |
| CA2690568A1 (en) * | 2007-06-20 | 2008-12-24 | Schering Corporation | Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease |
| US7720605B2 (en) | 2007-06-22 | 2010-05-18 | Weyerhaeuser Nr Company | Identifying vegetation attributes from LiDAR data |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| AR068767A1 (es) | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
| EP2628486A3 (en) | 2007-12-14 | 2013-10-30 | Amgen, Inc. | Method for treating bone fracture with anti-sclerostin antibodies |
| MX2010013239A (es) | 2008-06-03 | 2011-02-24 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| US20090301682A1 (en) | 2008-06-05 | 2009-12-10 | Baker Hughes Incorporated | Casting furnace method and apparatus |
| RU2011104348A (ru) | 2008-07-08 | 2012-08-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение |
| CN102164959A (zh) | 2008-09-29 | 2011-08-24 | 罗氏格黎卡特股份公司 | 针对人il17的抗体及其应用 |
| EP2358392B1 (en) | 2008-11-12 | 2019-01-09 | MedImmune, LLC | Antibody formulation |
| FR2938547B1 (fr) | 2008-11-14 | 2012-11-16 | Total Raffinage Marketing | Liant synthetique clair |
| WO2010065491A2 (en) | 2008-12-01 | 2010-06-10 | Carolus Therapeutics, Inc. | Methods of treating inflammatory disorders |
| SG10201402960SA (en) | 2009-03-05 | 2014-08-28 | Abbvie Inc | IL-17 Binding Proteins |
| RU2665954C1 (ru) | 2010-10-08 | 2018-09-05 | Новартис Аг | Способы лечения псориаза с использованием антагонистов il-17 |
| KR20140008305A (ko) * | 2010-11-05 | 2014-01-21 | 노파르티스 아게 | Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법 |
| AR084234A1 (es) * | 2010-12-13 | 2013-05-02 | Novartis Ag | Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17) |
| KR20140097178A (ko) | 2011-11-21 | 2014-08-06 | 노파르티스 아게 | IL-17 길항제 및 건선성 관절염 (PsA) 반응 또는 비-반응 대립유전자를 이용하여 PsA를 치료하는 방법 |
| AU2013249232A1 (en) | 2012-04-20 | 2014-10-09 | Novartis Ag | Methods of treating ankylosing spondylitis using IL-17 antagonists |
| WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| AU2016342578A1 (en) | 2015-10-19 | 2018-03-29 | Novartis Ag | Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (IL-17) antagonists |
| US11280479B2 (en) | 2017-10-18 | 2022-03-22 | The Sloan Company | Sign box light module |
-
2011
- 2011-11-04 KR KR1020137011539A patent/KR20140008305A/ko not_active Ceased
- 2011-11-04 SG SG2013023064A patent/SG189138A1/en unknown
- 2011-11-04 IL IL311014A patent/IL311014A/en unknown
- 2011-11-04 EP EP19162707.4A patent/EP3542820A1/en not_active Withdrawn
- 2011-11-04 SI SI201132138T patent/SI3757126T1/sl unknown
- 2011-11-04 MX MX2013005060A patent/MX362591B/es active IP Right Grant
- 2011-11-04 PT PT16163440T patent/PT3111954T/pt unknown
- 2011-11-04 SM SM20250423T patent/SMT202500423T1/it unknown
- 2011-11-04 LT LTEP16163440.7T patent/LT3111954T/lt unknown
- 2011-11-04 EP EP20187001.1A patent/EP3757126B1/en active Active
- 2011-11-04 SI SI201131750T patent/SI3111954T1/sl unknown
- 2011-11-04 US US13/877,585 patent/US9744234B2/en active Active
- 2011-11-04 KR KR1020187004058A patent/KR20180019247A/ko not_active Ceased
- 2011-11-04 LT LTEP20187001.1T patent/LT3757126T/lt unknown
- 2011-11-04 PL PL16163440T patent/PL3111954T3/pl unknown
- 2011-11-04 CA CA2813849A patent/CA2813849C/en active Active
- 2011-11-04 KR KR1020167014431A patent/KR20160067984A/ko not_active Ceased
- 2011-11-04 CA CA3116725A patent/CA3116725C/en active Active
- 2011-11-04 KR KR1020187034385A patent/KR20180129991A/ko not_active Ceased
- 2011-11-04 JP JP2013537154A patent/JP2014503482A/ja active Pending
- 2011-11-04 TW TW104103341A patent/TWI616204B/zh active
- 2011-11-04 ES ES16163440T patent/ES2733712T3/es active Active
- 2011-11-04 HU HUE16163440A patent/HUE044038T2/hu unknown
- 2011-11-04 TW TW105142587A patent/TWI618543B/zh active
- 2011-11-04 HR HRP20251174TT patent/HRP20251174T1/hr unknown
- 2011-11-04 WO PCT/EP2011/069476 patent/WO2012059598A2/en not_active Ceased
- 2011-11-04 DE DE20187001.1T patent/DE20187001T1/de active Pending
- 2011-11-04 DK DK16163440.7T patent/DK3111954T3/da active
- 2011-11-04 TR TR2019/09531T patent/TR201909531T4/tr unknown
- 2011-11-04 FI FIEP20187001.1T patent/FI3757126T3/fi active
- 2011-11-04 TW TW100140410A patent/TWI604851B/zh active
- 2011-11-04 EP EP21180656.7A patent/EP3912640B1/en active Active
- 2011-11-04 CN CN2011800529537A patent/CN103189074A/zh active Pending
- 2011-11-04 RU RU2013125775/15A patent/RU2582937C2/ru active
- 2011-11-04 ES ES20187001T patent/ES2804624T1/es active Pending
- 2011-11-04 RS RS20251090A patent/RS67377B1/sr unknown
- 2011-11-04 SG SG10201505624VA patent/SG10201505624VA/en unknown
- 2011-11-04 DK DK20187001.1T patent/DK3757126T3/da active
- 2011-11-04 EP EP16163440.7A patent/EP3111954B1/en not_active Revoked
- 2011-11-04 CN CN201510199026.8A patent/CN104800844A/zh active Pending
- 2011-11-04 KR KR1020157003096A patent/KR20150020734A/ko not_active Ceased
- 2011-11-04 EP EP22180976.7A patent/EP4116325A1/en active Pending
- 2011-11-04 PT PT201870011T patent/PT3757126T/pt unknown
- 2011-11-04 ES ES21180656T patent/ES3030036T3/es active Active
- 2011-11-04 EP EP11778903.2A patent/EP2635303A2/en not_active Withdrawn
- 2011-11-04 AU AU2011325134A patent/AU2011325134B2/en not_active Expired - Fee Related
- 2011-11-04 BR BR112013011176-3A patent/BR112013011176A2/pt not_active IP Right Cessation
- 2011-11-04 PH PH1/2013/500890A patent/PH12013500890A1/en unknown
-
2013
- 2013-03-18 IL IL225309A patent/IL225309B/en active IP Right Grant
- 2013-05-03 MA MA35873A patent/MA34647B1/fr unknown
- 2013-05-03 CL CL2013001213A patent/CL2013001213A1/es unknown
-
2015
- 2015-11-30 JP JP2015232562A patent/JP6049843B2/ja active Active
-
2016
- 2016-07-14 JP JP2016139469A patent/JP6250109B2/ja active Active
-
2017
- 2017-07-20 US US15/654,854 patent/US10363307B2/en active Active
- 2017-11-21 JP JP2017223669A patent/JP6515168B2/ja active Active
-
2018
- 2018-10-24 IL IL262559A patent/IL262559B/en unknown
-
2019
- 2019-04-12 JP JP2019076324A patent/JP2019142912A/ja active Pending
- 2019-06-12 US US16/439,423 patent/US20190307880A1/en not_active Abandoned
- 2019-06-26 HR HRP20191162TT patent/HRP20191162T1/hr unknown
- 2019-07-03 CY CY20191100708T patent/CY1121802T1/el unknown
-
2020
- 2020-03-19 US US16/824,613 patent/US11534491B2/en active Active
- 2020-12-18 US US17/127,758 patent/US20210128726A1/en not_active Abandoned
-
2021
- 2021-02-02 US US17/165,729 patent/US20210177966A1/en not_active Abandoned
- 2021-03-01 JP JP2021031383A patent/JP2021104995A/ja active Pending
- 2021-04-25 IL IL282625A patent/IL282625A/en unknown
- 2021-12-08 US US17/545,894 patent/US12465635B2/en active Active
-
2022
- 2022-10-21 US US18/048,797 patent/US20230293683A1/en active Pending
- 2022-12-02 US US18/061,221 patent/US20230346926A1/en active Pending
-
2023
- 2023-05-23 JP JP2023084472A patent/JP2023109910A/ja active Pending
-
2025
- 2025-02-24 US US19/061,831 patent/US20250205332A1/en active Pending
- 2025-03-04 JP JP2025034128A patent/JP2025102772A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34647B1 (fr) | Procedes de traitement de la polyarthriterhumatoide en utilisant des antagonistes dil-17 | |
| MA34646B1 (fr) | Procedes de traitement du psoriasis en utilisant des antagonistes d'il-17 | |
| MA35620B1 (fr) | Compositions pour le traitement de l'arthrite rhumatoïde et procédés d'utilisation desdites compositions | |
| JOP20180117B1 (ar) | أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها | |
| MA34461B1 (fr) | Anticorps anti-peptide beta-amyloide n3pgiu et leurs utilisations | |
| MA38161A1 (fr) | Anticorps anti-bmp-6 | |
| MA37946A1 (fr) | Traitement de la polyarthrite rhumatoïde | |
| DK1937721T3 (da) | Anti-IL-23 antistoffer | |
| PH12018500062A1 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| MA40476B1 (fr) | Anticorps et fragments de fixation à l'antigène anti-lag3 | |
| UA113623C2 (uk) | Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi) | |
| EA200702053A1 (ru) | Антитела против cd38 для лечения множественной миеломы | |
| UA115657C2 (uk) | Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла | |
| MA34907B1 (fr) | Molécules d'anticorps se liant à il-17a et il-17f | |
| MX2009008608A (es) | Anticuerpos monoclonales anti-cxcl13. | |
| MA45125B1 (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| MA34175B1 (fr) | Anticorps anti-cxcr4 humanisés pour le traitement de cancer | |
| MA47221A1 (fr) | Anticorps monoclonal à pd-l1 | |
| MA35173B1 (fr) | Anticorps anti-cxcr4 ayant des fonctions effectrices et son utilisation pour le traitement du cancer | |
| EA202191666A1 (ru) | Антитела к il-27 и их применение | |
| PH12014501985B1 (en) | Il-17 antibody formulation | |
| MA49607A1 (fr) | Anticorps monoclonal pour il-5ra | |
| MA34487B1 (fr) | Compositions d'anticorps anti-vegfr-3. | |
| MA45831B1 (fr) | Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation | |
| TN2013000144A1 (en) | Methods of treating rheumatoid arthuritis using il-17 antagonists |